Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00486421
Other study ID # CDR0000529883
Secondary ID P30CA015083MC048
Status Completed
Phase Phase 0
First received June 13, 2007
Last updated October 15, 2014
Start date January 2007
Est. completion date November 2008

Study information

Verified date October 2014
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

RATIONALE: Rituximab and prednisone may increase the number of platelets in patients with immune thrombocytopenic purpura.

PURPOSE: This phase II trial is studying the side effects and how well giving rituximab together with prednisone works as first-line therapy in treating patients with immune thrombocytopenic purpura.


Description:

OBJECTIVES:

Primary

- Determine the efficacy of rituximab, when administered with standard prednisone treatment, in maintaining a platelet count ≥ 50,000/mm³ at 6 months without further therapies (e.g., splenectomy or other salvage therapies) in patients with immune thrombocytopenic purpura.

- Determine the safety of this regimen in these patients.

Secondary

- Determine the time to platelet recovery in patients treated with this regimen.

- Determine the duration of platelet recovery in patients treated with this regimen.

- Assess efficacy of this regimen in preventing spontaneous bleeding events in these patients.

- Determine the response in patients treated with this regimen.

OUTLINE: This is a pilot study.

Patients receive rituximab IV on days 1, 8, 15, and 22 and oral prednisone once daily on days 1-14 followed by a taper to day 56. Treatment is administered in the absence of disease relapse or unacceptable toxicity.

After completion of study therapy, patients are followed periodically for up to 3 years.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date November 2008
Est. primary completion date May 2008
Accepts healthy volunteers No
Gender Both
Age group 21 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Diagnosis of immune thrombocytopenic purpura (ITP)

- Diagnosis must be made according to American Society of Hematology diagnostic guidelines by a member of Mayo Rochester's Division of Hematology/Oncology within the past year

- ITP must be confirmed by bone marrow aspiration and biopsy in all patients = 60 years of age*

- Bone marrow studies performed outside Mayo must be reviewed by a Mayo hematopathologist to confirm diagnosis and exclude evidence of other hematologic disorders NOTE: *Bone marrow evaluation is discretionary for all other patients

- Requires treatment, as defined by 1 of the following parameters:

- Platelet count = 30,000/mm³

- Platelet count = 50,000/mm³ with episodic bleeding (i.e., spontaneous or with minimal trauma) requiring treatment

- No concurrent diagnosis of a condition known to cause secondary immune (or nonimmune) thrombocytopenia, including, but not limited to, any of the following:

- Rheumatological conditions, such as lupus, rheumatoid arthritis, scleroderma, or mixed connective tissue disorder

- Patients with positive serologies and no concurrent, clinically evident condition are eligible

- HIV positive or AIDS

- Non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic lymphoma, multiple myeloma, or other malignant hematological conditions

- Clinically evident antiphospholipid antibody syndrome* or heparin-induced thrombocytopenia

- Clinically overt liver disease, hepatitis B surface antigen positive, hepatitis C serology positive, or evidence of a microangiopathic hemolytic anemia, such as disseminated intravascular coagulation, hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura, or preeclampsia NOTE: *Positive laboratory tests without the defined clinical criteria for a diagnosis of antiphospholipid antibody syndrome is allowed

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Creatinine = 2 times upper limit of normal (ULN)

- Direct bilirubin = 1.5 times ULN

- Total bilirubin = 1.5 times ULN

- AST = 2.5 times ULN

- Hemoglobin = 10 g/dL

- WBC = 3,000/mm³

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No hypersensitivity to murine or chimeric proteins

- No other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk for treatment complications

- Able to take a proton-pump inhibitor while on corticosteroids

- No unresolved or incompletely treated infection within the past 14 days

PRIOR CONCURRENT THERAPY:

- No prior corticosteroid therapy since the diagnosis of ITP

- Corticosteroid therapy is allowed for up to 14 days prior to study entry, once the baseline CBC has been established

- No prior rituximab

- No other concurrent therapy for ITP, including androgens, IV immunoglobulins, RH_o (D) immune globulin, cyclosporine, or azathioprine sodium

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
Rituximab
375mg/m2 IV weekly times 4 (days 1, 8, 15, 22)
Drug:
Prednisone
1mg/kg/d PO, taper to off by 8 weeks

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Mayo Clinic National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Failure-free survival at 6 months 6 months No
Secondary Time to platelet recovery 1 year No
Secondary Duration of platelet recovery 1 year No
Secondary Effect of treatment on prevention of spontaneous bleeding events 1 year No
See also
  Status Clinical Trial Phase
Recruiting NCT00986557 - T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant Phase 2
Completed NCT00132015 - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Phase 2
Active, not recruiting NCT00334672 - Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis Phase 3
Completed NCT01147991 - Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer Phase 1
Completed NCT00955591 - Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men N/A
Completed NCT01209325 - Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Phase 2
Terminated NCT01319526 - Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
Completed NCT00919997 - Human Papilloma Virus Infection in HIV-Positive Indian Men Who Have Sex With Men N/A
Completed NCT00822120 - S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Phase 2
Completed NCT00381875 - Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV Phase 1
Completed NCT00716911 - Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant N/A
Active, not recruiting NCT01490801 - Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma N/A
Completed NCT00722839 - Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants Phase 1
Completed NCT00981097 - Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Completed NCT00667563 - Vaccine Therapy in Preventing HPV in HIV-Positive Women in India Phase 1
Completed NCT01164722 - Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia Phase 3
Completed NCT00657410 - Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura Phase 3